Major Depressive Disorder

Latest News

bipolar
SAINT iTBS Protocol Shows Promise for Bipolar I Depression

November 4th 2024

A refined rTMS protocol, the Stanford Accelerated Intelligent Neuromodulation Therapy for major depressive disorder, shows promise in bipolar disorder.

Disappointing Phase 2b Results for ALTO-100 for MDD, Precision Medicine
Disappointing Phase 2b Results for ALTO-100 for MDD, Precision Medicine

October 23rd 2024

brain electric
rTMS for Antidepressant Nonresponders

October 21st 2024

vitamin d
Mental Health in the Sun: The Role of Vitamin D Deficiency in Mental Illness

October 16th 2024

Latest CME Events & Activities

Updates on New and Emerging Therapies to Improve Outcomes for Patients With Major Depressive Disorder

View More

PER® Psychiatry Summit

November 7, 2024

View More

5th Annual International Congress on the Future of Neurology®

View More

2023 Annual Psychiatric Times™ World CME Conference

View More

Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II

View More

Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies

View More

Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments

View More

'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care

View More

Real Psychiatry 2025

January 17 - 18, 2025

View More

More Than ‘Blue’ After Birth: Managing Diagnosis and Treatment of Post-Partum Depression

View More

Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans

View More

Expert Perspectives in the Recognition and Management of Postpartum Depression

View More

SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era

View More

Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists

View More

BURST CME™ Part I: Understanding the Impact of Huntington’s Disease

View More

Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease

View More

Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea

View More

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

View More

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

View More

More News

© 2024 MJH Life Sciences

All rights reserved.